['lung cancer', 'non-small cell lung cancer']
['bevacizumab', 'sb8', 'carboplatin', 'paclitaxel']

        Inclusion Criteria:

          1. Aged ≥ 18 years

          2. ECOG performance status of 0-1

          3. Histologically-confirmed metastatic or recurrent non-squamous non-small cell lung
             cancer

          4. At least one measurable lesion according to RECIST v1.1.

          5. Able to receive bevacizumab, carboplatin and paclitaxel based on adequate laboratory
             and clinical parameters

        Exclusion Criteria:

          1. Diagnosis of small cell carcinoma of the lung or squamous cell carcinoma

          2. Sensitizing EGFR mutations or ALK rearrangements

          3. Increased risk of bleeding determined by investigator based on radiographic / clinical
             findings

          4. History of systemic chemotherapy administered in the first-line setting for metastatic
             or recurrent disease of NSCLC.
      